NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NEKTAR THERAPEUTICS
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Aug 14, 2026
$36.64+0.86 (+2.40%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$21.13 (−36.58%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
NEKTAR THERAPEUTICS saw revenue fall 43.9% to $55.23M over the twelve months to Dec 31, 2025. Free cash flow was -$208.68M.
Revenue
$55.23M
-43.9% vs. a year earlier
Operating income
-$140.10M
TTM Q4 2025
Free cash flow
-$208.68M
TTM Q4 2025
EPS, diluted
-$9.73
TTM Q4 2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $55.23M
- Net income
- -$164.08M
- EPS, diluted
- -$9.73
- Free cash flow
- -$208.68M
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
$55.23M-43.9% YoY
Gross profit
$55.23M-18.5% YoY
Operating income
-$140.10M
Net income
-$164.08M
EPS, diluted
-$9.73
Free cash flow
-$208.68M
Reported period